Evidence map›Paper›PMID 25717109›Full record

ArticleJournal of virology2015

Oropouche virus infection and pathogenesis are restricted by MAVS, IRF-3, IRF-7, and type I interferon signaling pathways in nonmyeloid cells.

Jose Luiz Proenca-Modena, Renata Sesti-Costa, Amelia K Pinto, Justin M Richner, Helen M Lazear, Tiffany Lucas, Jennifer L Hyde, Michael S Diamond

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 83 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 2 countries.

Jose Luiz Proenca-ModenaDepartment of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA Department of Genetics, Evolution and Bioagents, Institute of Biology, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.
Renata Sesti-CostaDepartment of Pathology & Immunology, Washington University School of Medicine, St. Louis, Missouri, USA Department of Biochemistry and Immunology, University of São Paulo (USP) Ribeirão Preto School of Medicine, São Paulo, Brazil.
Amelia K PintoDepartment of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Justin M RichnerDepartment of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Helen M LazearDepartment of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Tiffany LucasDepartment of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Jennifer L HydeDepartment of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA.
Michael S DiamondDepartment of Medicine, Washington University School of Medicine, St. Louis, Missouri, USA Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, Missouri, USA Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, Missouri, USA Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, St. Louis, Missouri, USA diamond@wusm.wustl.edu.
Washington University in St. Louis · US

Funding

Washington University DDRCC Supplemental Equipment RequestP30DK052574 · NIDDK · WASHINGTON UNIVERSITY · PI Nicholas O. Davidson · 2000 to 2026
$30.8M
ISG CONTROL OF FLAVIVIRUS INFECTIONR01AI104972 · NIAID · WASHINGTON UNIVERSITY · PI CHANDA, SUMIT K, DIAMOND, MICHAEL S · 2013 to 2017
$3.0M
NIAID NIH HHS R01 AI104972NIDDK NIH HHS P30 DK052574NIDDK NIH HHS P30 DK52574
6 · The paper itself

Abstract

unlabelledOropouche virus (OROV) is a member of the Orthobunyavirus genus in the Bunyaviridae family and a prominent cause of insect-transmitted viral disease in Central and South America. Despite its clinical relevance, little is known about OROV pathogenesis. To define the host defense pathways that control OROV infection and disease, we evaluated OROV pathogenesis and immune responses in primary cells and mice that were deficient in the RIG-I-like receptor signaling pathway (MDA5, RIG-I, or MAVS), downstream regulatory transcription factors (IRF-3 or IRF-7), beta interferon (IFN-β), or the receptor for type I IFN signaling (IFNAR). OROV replicated to higher levels in primary fibroblasts and dendritic cells lacking MAVS signaling, the transcription factors IRF-3 and IRF-7, or IFNAR than in wild-type (WT) cells. In mice, deletion of IFNAR, MAVS, or IRF-3 and IRF-7 resulted in uncontrolled OROV replication, hypercytokinemia, extensive liver damage, and death, whereas WT congenic animals failed to develop disease. Unexpectedly, mice with a selective deletion of IFNAR on myeloid cells (CD11c Cre(+) Ifnar(f/f) or LysM Cre(+) Ifnar(f/f)) did not sustain enhanced disease with OROV or a selective (flox/flox) deletion La Crosse virus, a closely related encephalitic orthobunyavirus. In bone marrow chimera studies, recipient irradiated Ifnar(-/-) mice reconstituted with WT hematopoietic cells sustained high levels of OROV replication and liver damage, whereas WT mice reconstituted with Ifnar(-/-) bone marrow were resistant to disease. Collectively, these results establish a dominant protective role for MAVS, IRF-3 and IRF-7, and IFNAR in restricting OROV infection and tissue injury and suggest that IFN signaling in nonmyeloid cells contributes to the host defense against orthobunyaviruses. IMPORTANCE: Oropouche virus (OROV) is an emerging arthropod-transmitted orthobunyavirus that causes episodic outbreaks of a debilitating febrile illness in humans in countries of South and Central America. The continued expansion of the range and number of its arthropod vectors increases the likelihood that OROV will spread into new regions. At present, the pathogenesis of OROV in humans or other vertebrate animals remains poorly understood. To define cellular mechanisms of control of OROV infection, we performed infection studies in a series of primary cells and mice that were deficient in key innate immune genes involved in pathogen recognition and control. Our results establish that a MAVS-dependent type I IFN signaling pathway has a dominant role in restricting OROV infection and pathogenesis in vivo.

Indexed as

Signal TransductionAdaptor Proteins, Signal TransducingAnimalsBunyaviridae InfectionsCells, CulturedDisease Models, AnimalFibroblastsInterferon Regulatory Factor-3Interferon Regulatory Factor-7Interferon Type IMice, Inbred C57BLOrthobunyavirusSurvival AnalysisAdaptor Proteins, Signal TransducingInterferon Regulatory Factor-3Interferon Regulatory Factor-7Interferon Type IMAVS protein, mouse

Identifiers

PMID25717109
PMCPMC4403474
OpenAlexW2037005765

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.